seed
Stage
1
Investors
About
GlakoLens develops a non-invasive biosensor platform integrated into a contact lens for continuous 24-hour monitoring of intraocular pressure (IOP), enabling earlier and more accurate glaucoma diagnosis and personalized treatment options.
Explore GlakoLens's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.